background image background image background image

EV race heats up; Ferrari enters the EURO STOXX 50

Equities 5 minutes to read
Picture of Peter Garnry
Peter Garnry

Chief Investment Strategist

Summary:  The competition in battery electric vehicles continue to increase this year with Tesla introducing new price cuts in China on Friday and the Munich Motor Show over the weekend showing new exciting EV line-ups from BMW and Mercedes. For Tesla shareholders the key things to watch over the coming quarters are the operating margin and the global market share. In Europe, Ferrari will join the prestigious EURO STOXX 50 Index on 18 September and Novo Nordisk has become the most valuable European company.


Key points in this equity note

  • Competition in electric vehicles is heating up with new price cuts from Tesla and new exciting EV line-ups presented by Mercedes and BMW at the Munich Motor Show.

  • Ferrari enters the prestigious EURO STOXX 50 Index on 18 September 2023 marking an incredible run for the luxury carmaker since its IPO in 2016.

  • Novo Nordisk became the most valuable European company on Friday highlighting the enormous demand for its obesity drug. We continue to expect Novo Nordisk to be more valuable than many US technology companies in the years to come.

EV competitions heats up with price cuts and new Mercedes EV line-up

The global car industry is in constant change these years with carmakers rushing to catch up to Tesla’s lead in battery electric vehicles. Recently price cuts in China have been the key focus and on Friday Tesla’s share price declined 5% on news that it had cut EV prices again for the second time in two weeks suggesting increased competition from local carmakers. China’s passenger car sales is still below the highs made in late 2017 and early 2018 suggesting the market has matured and the 30-40 year rapid growth in cars is over.

4_PG_1
Tesla share price | Source: Saxo

In addition to intense competition in China’s EV, the general competition is heating up reminded at the weekend Munich Motor Show. Here, Mercedes presented their almost in production concept CLA sedan which is rated to go more than 750 kilometers on a charge beating Tesla’s newest upgrade to its Model 3. BMW also introduced new EV models at the Munich Motor Show. Both Mercedes and BMW are bolstering their line-up in the luxury segment which for now has escaped the intense price war that has started in the volume segment where Tesla’s Model 3 is competing. For Tesla shareholders the key thing to watch over the coming quarters is the market share developments. Tesla had roughly 32% market share in battery electric vehicles in 2022 which it has maintained so far in 2023, but should this slip over the coming year then it could change the narrative around the stock.

4_PG_2

Ferrari added to EURO STOXX 50 and Novo Nordisk becomes most valuable European company

Staying with the car theme, Qontigo (part of Deutsche Börse and owner of the EURO STOXX 50 Index) announced on Friday that Ferrari and Saint Gobain will be added to the EURO STOXX 50 Index effective 18 September 2023  while Vonovia and CRH will be deleted from the index. With Ferrari entering the most prestigious equity market benchmark marks the pinnacle of a fantastic growth journey since its IPO in 2016 with 12-month trailing revenue at €5.5bn up from €3.1bn in FY16 and 12-month trailing EBITDA at €2bn up from €874mn in FY16 highlighting the strong growth in the ultra-high-end of the luxury car market.

On Friday, Novo Nordisk became the most valuable European company stealing the limelight from ASML and LVMH that were the previous holders. Novo Nordisk’s market value is around €394bn in today’s session compared to LVMH at €390bn. The rise of Novo Nordisk over the previous two years riding the galloping demand for its obesity drug Wegovy has put health care companies, more specifically pharmaceuticals, to the top of European equity markets. Among the 10 most valuable companies in the STOXX 600 Index, four of those are now pharmaceutical companies (Novo Nordisk, Roche, Novartis, and AstraZeneca. As we have highlighted many times before the European equity market is more well-diversified than the US equity market and also have a higher exposure to defensive sectors that will do well in a downturn. It is not inconceivable that Novo Nordisk’s market value over time could eclipse that of many US technology companies as the company is fundamentally solving a far bigger problem that many technology companies. Novo Nordisk’s market value of $432bn is not far from Meta at $763bn (which was as low as $314bn at the end of 2022).

4_PG_3
EURO STOXX 50 | Source: Saxo

Latest Market Insights


Quarterly Outlook 2024 Q3

Sandcastle economics

01 / 05

  • 350x200 peter

    Macro: Sandcastle economics

    Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.

    Read article
  • 350x200 althea

    Bonds: What to do until inflation stabilises

    Discover strategies for managing bonds as US and European yields remain rangebound due to uncertain inflation and evolving monetary policies.

    Read article
  • 350x200 peter

    Equities: Are we blowing bubbles again

    Explore key trends and opportunities in European equities and electrification theme as market dynamics echo 2021's rally.

    Read article
  • 350x200 charu (1)

    FX: Risk-on currencies to surge against havens

    Explore the outlook for USD, AUD, NZD, and EM carry trades as risk-on currencies are set to outperform in Q3 2024.

    Read article
  • 350x200 ole

    Commodities: Energy and grains in focus as metals pause

    Energy and grains to shine as metals pause. Discover key trends and market drivers for commodities in Q3 2024.

    Read article

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)
Full disclaimer (https://www.home.saxo/legal/saxoselect-disclaimer/disclaimer)

Saxo Bank A/S (Headquarters)
Philip Heymans Alle 15
2900
Hellerup
Denmark

Contact Saxo

Select region

International
International

Trade responsibly
All trading carries risk. Read more. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more

This website can be accessed worldwide however the information on the website is related to Saxo Bank A/S and is not specific to any entity of Saxo Bank Group. All clients will directly engage with Saxo Bank A/S and all client agreements will be entered into with Saxo Bank A/S and thus governed by Danish Law.

Apple and the Apple logo are trademarks of Apple Inc, registered in the US and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.